Myelodysplastic Syndrome (MDS)

Advanced Disease

- Matched Related Donor
- Matched Unrelated
- Mismatched Unrelated
- dUCB

Haplo

BMT377
Phase I/II in Advanced Hematologic Malignancies
Undergoing Allogeneic HCT w/ Either Orca-T; a T-Cell-Depleted Graft w/ Additional Infusion of Conventional T Cells & Regulatory T Cells, or SoC Allogeneic Graft

PI: Meyer
Sponsor: Orca Biosystems

BMT343
Phase I/II, T-Cell-Depleted Graft +Conventional & Regulatory T Cells in Advanced Hematologic Malignancies

PI: Meyer
Sponsor: Orca Biosystems

BMT338
Phase I DonorGrafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies

PI: Meyer
Sponsor: Orca Biosystems

BMT391
Phase II HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies

PI: Arai
Sponsor: National Marrow Donor Program (NMDP)

BMT333_EXP
Phase III Expanded Access Omidubicel in Allogeneic Transplantation in Hematological Malignancies

PI: Rezvani
Sponsor: Gamida Cell

BMT372
Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

PI: Meyer
Sponsor: Stanford University

BMT342
Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT

PI: Johnston
Sponsor: Fred Hutchinson

KEY

- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu